Nenocorilant features among the latest industry projects newly into phase 1.
ApexOnco Front Page
Recent articles
In fit KMT2Ar patients the group will focus on Revuforj plus Venclexta and azacitidine.
Linker-MM4 data raise more questions about sequencing of therapies for multiple myeloma.
Tecvayli plus Darzalex could challenge Carvykti in the push for a functional cure.
Pfizer reveals the discontinuation of PF-08046044.
On efficacy, at least, BeOne’s BTK degrader shows an edge.
The company will try to get the Komzifti QTc prolongation warning removed.
Of 15 treatment-emergent adverse events, only one was deemed related to therapy.
